Yes saw (read) that coverage by NBC. Survax's p2 trial is still recruiting as of today and after that there will be three years for data collection for the primary endpoint of overall survival. And if successful, the company will run a P3 trial which will take several more years to recruit and complete. So at this point it is not a peer competitor.
In addition, Survax targets only one or two antigen (I don't remember exactly) while DCVax-L targets the whole set of antigens of the GBM tumors. So theoretically and also from what Linda Liau has done in UCLA, Survax should not work as good as DCVax-L.
As for why we have not seen any coverage on NBC yet, this is a mystery. They could be a lot of different explanations: it could be the US biotech mafia as someone has called them who hasn't reported our story as DCVax is a threat to what they have represented, ie, big pharms, or it may be DCVax story is not new. When DCVax-L in P1/2 trial and in early P3 trial, major US media did report in print and also in TVs.
But I read some tweets this morning, some GBM patient and investors have contacted the NBC lady who wrote the recent Survax story, asking her to get into DCVax-L story, particularly after P3 results have been published in JAMA Oncology. She seems to say she will follow.
Nothing we can do really. I am just patiently waiting the inevitable news. In the meanwhile, accumulate more shares as I have unwavering belief DCVax-L will be approved for GBM, followed by other solid cancers.
Best.